Breaking News: First Therapeutic Gene Therapy to Treat an Inherited Neuropathy is Approved for Clinical Trial!

by | Mar 6, 2015 | 9 comments

hhhThe first disease community to receive a therapeutic gene to the spinal cord for an ultra rare inherited neuropathy is Giant Axonal Neuropathy (GAN). Congratulations to Hannah’s Hope Fund (HHF), a 501(c)3 public charity, which has driven this collaborative research in less than six years. Six million dollars has been raised to date to fund pre-clinical and clinical research on this rare disease.

The Phase 1 trial is recruiting – info here: Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy patients. A benign viral vector known as adeno associated virus serotype 9 (AAV9) is the “Fed-Ex truck” delivering a healthy copy of the GAN gene to the nerves in the spinal cord of affected patients. It is administered by a lumbar puncture to the cerebral spinal fluid. This trial will be housed at the National Institutes of Health, in Bethesda, MD.

If the AAV9 vector is well tolerated in the central nervous system, this gene therapy vector can be used for any genetic disorder whose targets are motor and sensory neurons, and whose causal gene size is small enough to fit inside the viral capsid. This is a turning point for rare neurological diseases and the inherited neuropathy community in particular. The impact of this work can potentially help other forms of Charcot-Marie-Tooth (CMT) and related diseases. Our hope and prayers for a successful outcome go out to all the families with GAN!

Learn more on this topic

Related Blog Posts

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Taking Matters Into Your Own Hands

Do you have a rare form of CMT?

We were contacted recently from a patient with CMT2D who was looking for advice on how to make a difference. Our recommendations for all people with an ultra-rare form of CMT who want to get involved:

Now GRIN is Accessible in 141 Different Languages!

Now GRIN is Accessible in 141 Different Languages!

The Global Registry for Inherited Neuropathies (GRIN) has implemented Google Translate. Why did we choose Google? Because Google is leading the way in teaching computers how to interpret meaning, avoiding the traditional method of decoding language.

Accelerating Patient Access to Investigational Drugs in 2015

Accelerating Patient Access to Investigational Drugs in 2015

Currently the FDA is working to update the process for physicians applying for accelerated patient access to investigational drugs, while the drug or biological product is being tested in clinical trials. This will also be important for the CMT community as clinical trials for this disease are being launched.

Do You Have Charcot-Marie-Tooth Type 4 (CMT4)? – We Need Your Help

Autosomal recessive demyelinating CMT4 patients present with earlyonset and slowly progressing symptoms. These include progressive distally accentuated weakness and atrophy of muscles in the lower limbs. In addition, patients may have weakness and atrophy of hands, sensory loss and pes cavus (high-arched feet), and walking difficulties. Further information on CMT4 can be found at Orphanet.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Join the conversation

Leave a Comment

9 Comments

  1. Alexander

    Hi there, I have the variant of Charcot Marie tooth syndrome CMTX-6 with a mutation in the PDK3 gene. Is there the possibility that this treatment can be used for my neuropathy? If so, how many years could it be until it is able to be used seeing it is among the rarest of its type? I’m from Australia

    Reply
  2. Madiha shahid

    Hi i m madiha Shahid and m suffering in inherited neutopathy my age is 33 and m in Australia plz let me know how could i try this gene therapy
    Thnx

    Reply
  3. sajad

    Hi,
    I am about 30 years old and I have charcot Marie tooth,but fortunately I can walk and run, .my most significant problem is weakness of my foot muscles. I am trying to make them stronger. According to my research, a drug called PXT-3003has been manufactured. I’d like to know if this drug is effective and available.
    Mean while, I would like to know that ,how long does it takes for gene therapy to be a public treatment.
    Thanks

    Reply
  4. Bonita Brown

    Please send me all the information on gene therapy for Charcot-Marie-Tooth. Thank you so much

    Reply
  5. Michele

    Is Charcot Marie Tooth 1b a good requirement in order to partecipate to above clinical trial ??
    Let me now.
    Thanks.

    Reply
  6. Zahir Akhtar

    Hi, I too have a hereditary neuropathy disease called Charcot Marie-Tooth and would like to know if there are any trial therapies for curing this condition available in London UK…

    Reply

Leave a Reply to Madiha shahid Cancel reply

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news